NYON, Switzerland, August 25 /PRNewswire/ -- Mymetics Corporation (OTCBB:MYMX) announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.
In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Mymetics Corporation will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.
Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.
Mymetics have further contracted with BlueSkyMLS http://www.blueskymls.com to seek registration in states not covered by the S&P Market Access Program.
Ernest Luebke, Chief Financial Officer of Mymetics Corporation stated "We are very pleased with the level of professionalism demonstrated by Standard & Poor's as well as BlueSkyMLS in assisting us with our US exemption process."
About Mymetics Corporation
Mymetics' primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus, or HIV, the virus that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has also recently acquired from a close scientific partner an advanced malaria vaccine project currently in phase Ib clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for human oncoviral leukemias, multiple sclerosis, and organ transplantation.
Contacts: Anthony Jessop Senior Vice President Mymetics, Inc. tel: North America +1-303-800-6606 ajessop@mymetics.com Standard & Poor's Customer Contact: Richard Albanese +1-212-438-3647 richard_albanese@sandp.com Standard and Poor's Media Relations Contact: Michael Privitera +1-212-438-6679 michael_privitera@sandp.com BlueSkyMLS Contact : Theodore J. Dragon +1-201-804-3909 x 113 tdragon@blueskymls.com
Contacts: Anthony Jessop, Senior Vice President Mymetics, Inc., tel: North America +1-303-800-6606, ajessop@mymetics.com; Standard & Poor's Customer Contact: Richard Albanese, +1-212-438-3647, richard_albanese@sandp.com; Standard and Poor's Media Relations Contact: Michael Privitera, +1-212-438-6679, michael_privitera@sandp.com; BlueSkyMLS Contact : Theodore J. Dragon, +1-201-804-3909 x 113, tdragon@blueskymls.com
Comments